Predicting uniaxial compressive strength of rocks using ANN models: Incorporating porosity, compressional wave velocity, and schmidt hammer data.

The unconfined compressive strength (UCS) of intact rocks is crucial for engineering applications, but traditional laboratory testing is often impractical, especially for historic buildings lacking sufficient core samples. Non-destructive tests like the Schmidt hammer rebound number and compressional wave velocity offer solutions, but correlating these with UCS requires complex mathematical models. This paper introduces a novel approach using an artificial neural network (ANN) to simultaneously correlate UCS with three non-destructive test indexes: Schmidt hammer rebound number, compressional wave velocity, and open-effective porosity. The proposed ANN model outperforms existing methods, providing accurate UCS predictions for various rock types. Contour maps generated from the model offer practical tools for geotechnical and geological engineers, facilitating decision-making in the field and enhancing educational resources. This integrated approach promises to streamline UCS estimation, improving efficiency and accuracy in engineering assessments of intact rock materials.

Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.

This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval of tyrosine kinase inhibitors. Most patients (63%) had received first-line intensive therapy with 3 + 7. Subsequently, patients received salvage with intensive therapy (n = 261), non-intensive therapy (n = 63) or supportive care only (n = 80). Active salvage therapy (i.e., intensive or non-intensive therapy) resulted in a complete remission (CR) or CR without hematological recovery (CRi) rate of 42%. More patients achieved a CR/CRi with intensive (48%) compared with non-intensive (19%) salvage therapy (p < 0.001). In the overall population, median overall survival (OS) was 5.5 months; 1- and 5-year OS rates were 25% and 7%. OS was significantly (p < 0.001) prolonged with intensive or non-intensive salvage therapy compared with supportive therapy, and in those achieving CR/CRi versus no responders. Of 280 evaluable patients, 61 (22%) had an allogeneic stem-cell transplant after they had achieved CR/CRi. In conclusion, in this large cohort study, salvage treatment approaches for patients with FLT3-ITD mutated R/R AML were heterogeneous. Median OS was poor with both non-intensive and intensive salvage therapy, with best long-term outcomes obtained in patients who achieved CR/CRi and subsequently underwent allogeneic stem-cell transplant.